m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG03855)
Name
Autologous cell based gene therapy
Synonyms
Autologous cell based gene therapy (pulmonary hypertension)
    Click to Show/Hide
Status
Phase 1
TTD Drug ID
D0H3GK
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Nitric oxide synthase endothelial (NOS3)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Nitric oxide synthase endothelial (NOS3) is a therapeutic target for Autologous cell based gene therapy. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Autologous cell based gene therapy through regulating the expression of Nitric oxide synthase endothelial (NOS3). [1], [2]
References
Ref 1 N6-Methyladenosine Demethylase FTO (Fat Mass and Obesity-Associated Protein) as a Novel Mediator of Statin Effects in Human Endothelial Cells. Arterioscler Thromb Vasc Biol. 2022 May;42(5):644-658. doi: 10.1161/ATVBAHA.121.317295. Epub 2022 Mar 17.
Ref 2 Nitric oxide synthase inhibition with the antipterin VAS203 improves outcome in moderate and severe traumatic brain injury: a placebo-controlled randomized Phase IIa trial (NOSTRA). J Neurotrauma. 2014 Oct 1;31(19):1599-606. doi: 10.1089/neu.2014.3344. Epub 2014 Jul 28.